InvestorsObserver
Sign Up Login

ATOS Atossa Therapeutics Inc

$0.96 $0.00 (0.00%)
Add to Watchlist Compare
Overall

ATOS Stock Analysis Overview

What this means: Atossa Therapeutics Inc (ATOS) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ATOS's 56 means that it ranks higher than 56% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ATOS Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ATOS Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ATOS Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ATOS Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ATOS Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ATOS Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ATOS Stock Analysis Overview

What this means: Atossa Therapeutics Inc (ATOS) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ATOS's 56 means that it ranks higher than 56% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ATOS report

ATOS Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ATOS Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ATOS Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ATOS Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ATOS Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ATOS Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Atossa Therapeutics Inc (ATOS) Analyst Forecast

ATOS Price, Volume, Earnings, and Dividend Date

  • Last Price $0.96
  • Previous Close $0.96
  • Change $0.00
  • Open $0.92
  • Volume 1,105,300
  • Avg. Volume (100-day) 1,935,113
  • Market Cap 121,305,897
  • Days Range 0.88 - 0.9699
  • 52-week Range 0.84 - 9.8
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 02/11/20
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.531
  • PEG Ratio —

Atossa Therapeutics Inc (ATOS) Company Description

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Inc (ATOS) Stock Chart

View Interactive ATOS chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Trevi Therapeutics Inc (TRVI) (TRVI) $2.39
Point Biopharma Global Inc (PNT) (PNT) $8.12
Concert Pharmaceutic (CNCE) (CNCE) $5.88
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $20.99
Adma Biologics (ADMA) (ADMA) $2.04
Veru Inc (VERU) (VERU) $12.83
Chemocentryx Inc (CCXI) (CCXI) $23.41
Mirum Pharmaceuticals Inc (MIRM) (MIRM) $24.76
Catalyst Bio (CBIO) (CBIO) $1.23
Vaxcyte Inc (PCVX) (PCVX) $26.09